Johnson & Johnson (JNJ) closed at $255.60 on Oct 16, 2026, up 0.9% on the day. The stock is down 5.4% over the past month, up 2.7% over three months, up 24.2% year to date and up 35.3% over the past year. It trades 9.1% below its 52-week high of $281.07 and 40.0% above its 52-week low of $182.52. The close sits below its 50-day moving average ($265.23) and above its 200-day moving average ($243.91).
NextPick tracks JNJ in its Pharma basket alongside ABBV, MRK, RHHBY, NVS and AZN. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month JNJ ranks 11th of 12 basket members by price change.
Over its last 8 reports the stock moved an average of 2.3% on the first trading day after earnings, beating the options-implied move in 2 of 8.
JNJ options were pricing 26% at-the-money implied volatility on Oct 8, 2026, an IV rank of 75 over the past year.
Over the last 8 reports, JNJ moved an average of 2.3% on the first trading day after earnings. The move beat the options-implied move in 2 of 8 reports.
Yes — the Oct 16, 2026 close of $255.60 is 4.8% above the 200-day average of $243.91.
JNJ closed 9.1% below its 52-week high of $281.07.
NextPick groups JNJ with ABBV, MRK, RHHBY, NVS and AZN in its Pharma basket.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
